Gieseler F - Search Results

1

Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon.

Kurz EU, Leader KB, Kroll DJ, Clark M, Gieseler F. Kurz EU, et al. Among authors: gieseler f. J Biol Chem. 2000 May 5;275(18):13948-54. doi: 10.1074/jbc.275.18.13948. J Biol Chem. 2000. PMID: 10788521 Free article.

2

Are topoisomerase II inhibitor-induced micronuclei in vitro a predictive marker for the compounds' ability to cause secondary leukemias after treatment?

Stopper H, Boos G, Clark M, Gieseler F. Stopper H, et al. Among authors: gieseler f. Toxicol Lett. 1999 Jan 11;104(1-2):103-10. doi: 10.1016/s0378-4274(98)00353-1. Toxicol Lett. 1999. PMID: 10048755

3

Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.

Gieseler F, Bauer E, Nuessler V, Clark M, Valsamas S. Gieseler F, et al. Leukemia. 1999 Nov;13(11):1859-63. doi: 10.1038/sj.leu.2401570. Leukemia. 1999. PMID: 10557063

4

Alteration of topoisomerase II action is a possible molecular mechanism of HL-60 cell differentiation.

Gieseler F, Boege F, Clark M. Gieseler F, et al. Environ Health Perspect. 1990 Aug;88:183-5. doi: 10.1289/ehp.9088183. Environ Health Perspect. 1990. PMID: 2176973 Free PMC article.

5

Use of anion-exchange chromatography and chromatofocusing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatment.

Boege F, Gieseler F, Biersack H, Clark M. Boege F, et al. Among authors: gieseler f. J Chromatogr. 1991 Nov 29;587(1):3-9. doi: 10.1016/0021-9673(91)85191-h. J Chromatogr. 1991. PMID: 1664428

6

Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.

Gieseler F, Boege F, Clark M, Meyer P. Gieseler F, et al. Toxicol Lett. 1993 Apr;67(1-3):331-40. doi: 10.1016/0378-4274(93)90066-7. Toxicol Lett. 1993. PMID: 8383890

7

Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.

Gieseler F, Glasmacher A, Kämpfe D, Zernak C, Valsamas S, Kunze J, Clark M. Gieseler F, et al. Recent Results Cancer Res. 1997;143:321-7. doi: 10.1007/978-3-642-60393-8_22. Recent Results Cancer Res. 1997. PMID: 8912429 No abstract available.

8

Nuclear Topoisomerase II Activity Changes During HL-60 Leukemic Cell Differentiation: Alterations in Drug Sensitivity and pH Dependency.

Gieseler F, Boege F, Biersack H, Spohn B, Clark M, Wilms K. Gieseler F, et al. Leuk Lymphoma. 1991;5(4):273-9. doi: 10.3109/10428199109068137. Leuk Lymphoma. 1991. PMID: 27467850

9

Induction of apoptosis by idarubicin: how important is the plasma peak?

Gieseler F, Clark M, Stiebeling K, Puschmann M, Valsamas S. Gieseler F, et al. Int J Clin Pharmacol Ther. 2000 Apr;38(4):217-21. doi: 10.5414/cpp38217. Int J Clin Pharmacol Ther. 2000. PMID: 10783832

10

Activation of the coagulation system in cancerogenesis and metastasation.

Xie WZ, Leibl M, Clark MR, Dohrmann P, Kunze T, Gieseler F. Xie WZ, et al. Among authors: gieseler f. Biomed Pharmacother. 2005 Apr;59(3):70-5. doi: 10.1016/j.biopha.2005.01.001. Biomed Pharmacother. 2005. PMID: 15795099 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters